{"log_id": 1841958470091517878, "direction": 0, "words_result_num": 30, "words_result": [{"probability": {"variance": 4e-06, "average": 0.99918, "min": 0.98788}, "location": {"width": 972, "top": 155, "height": 43, "left": 100}, "words": "但并非出现在所有患者中。这些皮疹通常是对抗组胺药和局部类固醇有反应。偶尔需要应用"}, {"probability": {"variance": 1e-05, "average": 0.998229, "min": 0.991797}, "location": {"width": 119, "top": 216, "height": 27, "left": 103}, "words": "全身类固醇"}, {"probability": {"variance": 0.000249, "average": 0.996697, "min": 0.899604}, "location": {"width": 922, "top": 255, "height": 37, "left": 150}, "words": "在高达1/3的使用伊马替尼治疗各适应症的患者中观察到有皮疹发生。这些皮疹常伴瘙"}, {"probability": {"variance": 2e-06, "average": 0.999038, "min": 0.994013}, "location": {"width": 970, "top": 303, "height": 38, "left": 102}, "words": "痒,且最常出现的是红斑,前臂、躯体或面部的斑丘疹皮损。皮肤活检显示出药物毒性反应"}, {"probability": {"variance": 6e-06, "average": 0.998688, "min": 0.986866}, "location": {"width": 967, "top": 351, "height": 38, "left": 105}, "words": "合并混合细胞浸润。虽然大多数皮疹程度轻微并且是自限性的,但较为严重者可能需要中断"}, {"probability": {"variance": 3.4e-05, "average": 0.997908, "min": 0.971955}, "location": {"width": 956, "top": 398, "height": 39, "left": 106}, "words": "或终止治疗。在GIST辅助治疗试验中皮肤反应的发生率较安慰剂组的高,这一点并不奇怪"}, {"probability": {"variance": 0, "average": 0.999686, "min": 0.999466}, "location": {"width": 77, "top": 456, "height": 27, "left": 102}, "words": "肝毒性"}, {"probability": {"variance": 3e-06, "average": 0.999156, "min": 0.989439}, "location": {"width": 920, "top": 495, "height": 36, "left": 153}, "words": "可能会发生肝毒性,偶见严重,且在临床前和临床上均已观察到。肝功能检查异常,通"}, {"probability": {"variance": 2e-06, "average": 0.999302, "min": 0.991138}, "location": {"width": 968, "top": 542, "height": 38, "left": 105}, "words": "常为转氨酶轻度升高,但少数患者的胆红素水平升高,一般在治疗的前两个月内发生,但最"}, {"probability": {"variance": 1e-06, "average": 0.999482, "min": 0.995977}, "location": {"width": 944, "top": 590, "height": 38, "left": 105}, "words": "迟在治疗开始后6至12个月也有发生。这些指标水平通常在停止治疗1~4周后恢复正常"}, {"probability": {"variance": 1e-06, "average": 0.999425, "min": 0.998016}, "location": {"width": 145, "top": 647, "height": 27, "left": 106}, "words": "低磷酸盐血症"}, {"probability": {"variance": 0.003392, "average": 0.986755, "min": 0.626981}, "location": {"width": 922, "top": 687, "height": 37, "left": 154}, "words": "在治疗各适应症中观察到血清磷酸盐偏低和低磷酸盐血症(高达3/4级)较为常见,但尚未"}, {"probability": {"variance": 2.3e-05, "average": 0.998456, "min": 0.969706}, "location": {"width": 947, "top": 734, "height": 39, "left": 104}, "words": "确定这一发现的来源和临床意义。伊马替尼已被证明可抑制人体单核细胞分化为破骨细胞"}, {"probability": {"variance": 7e-06, "average": 0.998911, "min": 0.98525}, "location": {"width": 970, "top": 782, "height": 38, "left": 106}, "words": "这一下降同时伴有这些细胞的再吸收能力也下降。在伊马替尼存在条件下,在破骨细胞中观"}, {"probability": {"variance": 0.001188, "average": 0.993152, "min": 0.773044}, "location": {"width": 971, "top": 831, "height": 37, "left": 106}, "words": "察到RANK-L呈剂量依赖性下降。持续抑制破骨细胞活性可能导致反调节应答,造成PTH"}, {"probability": {"variance": 1.2e-05, "average": 0.998387, "min": 0.983413}, "location": {"width": 958, "top": 878, "height": 39, "left": 106}, "words": "水平上升。临床前研究结果的临床相关性尚不清楚,与骨折等骨骼不良事件的关系尚未证实"}, {"probability": {"variance": 1e-06, "average": 0.99941, "min": 0.996376}, "location": {"width": 923, "top": 926, "height": 38, "left": 155}, "words": "在临床开发计划中,血清磷酸盐并不是在所有研究中常规检测的项目。虽然最初推测低"}, {"probability": {"variance": 0.003125, "average": 0.988556, "min": 0.628057}, "location": {"width": 970, "top": 974, "height": 39, "left": 108}, "words": "磷酸盐血症可能是剂量依赖性的,但来自ⅢI期TOPS研究(旨在探讨在新诊断CML患者中的"}, {"probability": {"variance": 3.3e-05, "average": 0.997641, "min": 0.96294}, "location": {"width": 969, "top": 1023, "height": 39, "left": 108}, "words": "安全性终点的剂量依赖性)的24个月的可解释的结果表明,接受400mg和800mg的患者发生"}, {"probability": {"variance": 0.00604, "average": 0.963116, "min": 0.556653}, "location": {"width": 810, "top": 1072, "height": 39, "left": 108}, "words": "的34级血清磷酸盐或血清钙水平下降分别为19.1%vs.15.5%和51%vs0.9%"}, {"probability": {"variance": 1e-06, "average": 0.999133, "min": 0.997036}, "location": {"width": 268, "top": 1127, "height": 29, "left": 110}, "words": "胃肠道梗阻、穿孔或溃疡"}, {"probability": {"variance": 0.047656, "average": 0.741097, "min": 0.462999}, "location": {"width": 118, "top": 1082, "height": 93, "left": 762}, "words": "森药业股"}, {"probability": {"variance": 2e-05, "average": 0.99787, "min": 0.981018}, "location": {"width": 922, "top": 1167, "height": 38, "left": 157}, "words": "在使用伊马替尼治疗各适应症的一小部分患者中已观察到胃肠道溃疡,在极大部分病例"}, {"probability": {"variance": 9e-06, "average": 0.99884, "min": 0.982096}, "location": {"width": 966, "top": 1214, "height": 40, "left": 112}, "words": "中可能表现为局部刺激。肿瘤出血肿瘤坏死,梗阻和胃肠道穿孔似乎是与疾病相关的,且仅"}, {"probability": {"variance": 3.2e-05, "average": 0.997201, "min": 0.979139}, "location": {"width": 967, "top": 1263, "height": 37, "left": 112}, "words": "在或更常见于在GIST患者中发生。在转移性GIST的病例中,在肿瘤反应中可能发生肿瘤坏"}, {"probability": {"variance": 0.00283, "average": 0.990366, "min": 0.646322}, "location": {"width": 969, "top": 1310, "height": 37, "left": 110}, "words": "死,很少会导致穿孔。胃肠道梗阻/肠梗阻在GIST群体(该情况可能是由于转移性GIST的"}, {"probability": {"variance": 2.4e-05, "average": 0.998551, "min": 0.9734}, "location": {"width": 666, "top": 1359, "height": 38, "left": 111}, "words": "肿瘤梗阻造成的)中以及既往GI手术粘连的辅助治疗中最常见"}, {"probability": {"variance": 0, "average": 0.999296, "min": 0.997856}, "location": {"width": 172, "top": 1414, "height": 30, "left": 111}, "words": "肿瘤溶解综合征"}, {"probability": {"variance": 3e-06, "average": 0.999043, "min": 0.991201}, "location": {"width": 922, "top": 1452, "height": 41, "left": 160}, "words": "肿瘤溶解综合征和伊马替尼治疗之间的因果关系被认为是可能的,但是一些病例可能与"}, {"probability": {"variance": 0.000105, "average": 0.995656, "min": 0.959877}, "location": {"width": 369, "top": 1506, "height": 35, "left": 112}, "words": "合并用药及其它独立风险因素相关"}], "language": 3}